JOP. J Pancreas (Online) 2004; 5(5):388-391.
Olanzapine-Induced Pancreatitis: A Case Report
Christian Waage1, Hans Carlsson2, Erik Waage Nielsen1,3
1Department of Anesthesiology and 2Department of Medicine, Nordland Hospital. Bodo, Norway. 3University of Tromso. Tromso, Norway
Context The antipsychotic agent clozapine has been linked to several cases of pancreatitis. The newer, but related, olanzapine was believed to have fewer side effects.
Case report A 42-year-old man in good physical condition gradually developed hypertriglyceridemia, hypercholesterolemia, elevated alanine aminotransferase, diabetes and, ultimately, acute pancreatitis after 19 months of olanzapine monotherapy. Due to multiorgan failure, he was in the intensive care unit and surgical ward for 29 days. He made a full recovery. The olanzapine was discontinued. Glucose, triglyceride and cholesterol levels normalized as did pancreas and liver function.
Conclusions We report olanzapine as the probable cause of acute pancreatitis in a patient without any known predisposing factors. Olanzapine-treated patients should be monitored with glucose, lipid, pancreatic function and liver function tests, and the olanzapine should be discontinued if the results of these tests worsen.
- Medicines and Health Care. Oslo, Norway: Norwegian Association of Pharmaceutical Manufacturers, 2004. Page 86. [More details]
- Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000; 20:844-7. [More details]
- Koller EA, Cross JT, Doraiswamy PM, Malozowski SN. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003; 23:1123-30. [More details]
- Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58:108-11. [More details]
- Cerulli TR. Clozapine-associated pancreatitis. Harv Rev Psychiatry 1999; 7:61-3. [More details]
- Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40:438-43. [More details]
- Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27-38. [More details]
- Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361:1581-9. [More details]
- Eli Lilly. Data Sheet. ZYPREXA™ & ZYPREXA ZYDIS™ Olanzapine tablets 2.5 mg, 5 mg, 10 mg. Olanzapine wafers 5 mg, 10 mg. Information for Health Proffesionals. Auckland, New Zealand: Eli Lilly and Company (NZ) Limited, 2004. [More details]
- Wetterling T. Diabetes Mellitus Type II - Induced by 'Atypical' Neuroleptics? Fortschr Neurol Psychiatr 2003; 71:312-22. [More details]
- Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine- treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61:742-9. [More details]
- Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand 2002; 105:235-6. [More details]
- Doucette DE, Grenier JP, Robertson PS. Olanzapine-induced acute pancreatitis. Ann Pharmacother 2000; 34:1128-31. [More details]
- Hagger R, Brown C, Hurley P. Olanzapine and pancreatitis. Br J Psychiatry 2000; 177:567. [More details]
- Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35:1556-8. [More details]
Keywords Antipsychotic Agents /adverse effects; Diabetes Mellitus; Pancreatitis
Correspondence Erik Waage Nielsen: email@example.com